Your browser doesn't support javascript.
Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019-United States, January 17-February 29, 2020.
McGovern, Olivia L; Stenger, Mark; Oliver, Sara E; Anderson, Tara C; Isenhour, Cheryl; Mauldin, Matthew R; Williams, Nia; Griggs, Eric; Bogere, Tonny; Edens, Chris; Curns, Aaron T; Lively, Joana Y; Zhou, Yingtao; Xu, Songli; Diaz, Maureen H; Waller, Jessica L; Clarke, Kevin R; Evans, Mary E; Hesse, Elisabeth M; Morris, Sapna Bamrah; McClung, Robert P; Cooley, Laura A; Logan, Naeemah; Boyd, Andrew T; Taylor, Allan W; Bajema, Kristina L; Lindstrom, Stephen; Elkins, Christopher A; Jones, Christopher; Hall, Aron J; Graitcer, Samuel; Oster, Alexandra M; Fry, Alicia M; Fischer, Marc; Conklin, Laura; Gokhale, Runa H.
  • McGovern OL; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Stenger M; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Oliver SE; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Anderson TC; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Isenhour C; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Mauldin MR; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Williams N; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Griggs E; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Bogere T; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Edens C; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Curns AT; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Lively JY; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Zhou Y; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Xu S; IHRC Inc., Contracting Agency to the Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Diaz MH; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Waller JL; Maximus Federal, Contracting Agency to the Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Clarke KR; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Evans ME; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Hesse EM; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Morris SB; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • McClung RP; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Cooley LA; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Logan N; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Boyd AT; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Taylor AW; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Bajema KL; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Lindstrom S; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Elkins CA; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Jones C; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Hall AJ; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Graitcer S; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Oster AM; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Fry AM; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Fischer M; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Conklin L; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Gokhale RH; CDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
PLoS One ; 16(4): e0249901, 2021.
Article in English | MEDLINE | ID: covidwho-1186608
Semantic information from SemMedBD (by NLM)
1. 2019 novel coronavirus CAUSES COVID-19
Subject
2019 novel coronavirus
Predicate
CAUSES
Object
COVID-19
2. Personal assessment TREATS COVID-19
Subject
Personal assessment
Predicate
TREATS
Object
COVID-19
3. Real-Time Polymerase Chain Reaction METHOD_OF disease prevention
Subject
Real-Time Polymerase Chain Reaction
Predicate
METHOD_OF
Object
disease prevention
4. 2019 novel coronavirus CAUSES COVID-19
Subject
2019 novel coronavirus
Predicate
CAUSES
Object
COVID-19
5. Personal assessment TREATS COVID-19
Subject
Personal assessment
Predicate
TREATS
Object
COVID-19
6. Real-Time Polymerase Chain Reaction METHOD_OF disease prevention
Subject
Real-Time Polymerase Chain Reaction
Predicate
METHOD_OF
Object
disease prevention
ABSTRACT

BACKGROUND:

The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), evolved rapidly in the United States. This report describes the demographic, clinical, and epidemiologic characteristics of 544 U.S. persons under investigation (PUI) for COVID-19 with complete SARS-CoV-2 testing in the beginning stages of the pandemic from January 17 through February 29, 2020.

METHODS:

In this surveillance cohort, the U.S. Centers for Disease Control and Prevention (CDC) provided consultation to public health and healthcare professionals to identify PUI for SARS-CoV-2 testing by quantitative real-time reverse-transcription PCR. Demographic, clinical, and epidemiologic characteristics of PUI were reported by public health and healthcare professionals during consultation with on-call CDC clinicians and subsequent submission of a CDC PUI Report Form. Characteristics of laboratory-negative and laboratory-positive persons were summarized as proportions for the period of January 17-February 29, and characteristics of all PUI were compared before and after February 12 using prevalence ratios.

RESULTS:

A total of 36 PUI tested positive for SARS-CoV-2 and were classified as confirmed cases. Confirmed cases and PUI testing negative for SARS-CoV-2 had similar demographic, clinical, and epidemiologic characteristics. Consistent with changes in PUI evaluation criteria, 88% (13/15) of confirmed cases detected before February 12, 2020, reported travel from China. After February 12, 57% (12/21) of confirmed cases reported no known travel- or contact-related exposures.

CONCLUSIONS:

These findings can inform preparedness for future pandemics, including capacity for rapid expansion of novel diagnostic tests to accommodate broad surveillance strategies to assess community transmission, including potential contributions from asymptomatic and presymptomatic infections.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0249901

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Male / Middle aged / Young adult Country/Region as subject: North America Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0249901